These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963 [TBL] [Abstract][Full Text] [Related]
5. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. Abriel H; Cabo C; Wehrens XH; Rivolta I; Motoike HK; Memmi M; Napolitano C; Priori SG; Kass RS Circ Res; 2001 Apr; 88(7):740-5. PubMed ID: 11304498 [TBL] [Abstract][Full Text] [Related]
6. A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation. Keller DI; Acharfi S; Delacrétaz E; Benammar N; Rotter M; Pfammatter JP; Fressart V; Guicheney P; Chahine M J Mol Cell Cardiol; 2003 Dec; 35(12):1513-21. PubMed ID: 14654377 [TBL] [Abstract][Full Text] [Related]
7. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Fredj S; Sampson KJ; Liu H; Kass RS Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744 [TBL] [Abstract][Full Text] [Related]
8. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Wei J; Wang DW; Alings M; Fish F; Wathen M; Roden DM; George AL Circulation; 1999 Jun; 99(24):3165-71. PubMed ID: 10377081 [TBL] [Abstract][Full Text] [Related]
9. Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes. Baroudi G; Chahine M FEBS Lett; 2000 Dec; 487(2):224-8. PubMed ID: 11150514 [TBL] [Abstract][Full Text] [Related]
10. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. Rivolta I; Abriel H; Tateyama M; Liu H; Memmi M; Vardas P; Napolitano C; Priori SG; Kass RS J Biol Chem; 2001 Aug; 276(33):30623-30. PubMed ID: 11410597 [TBL] [Abstract][Full Text] [Related]
11. A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response. Bankston JR; Yue M; Chung W; Spyres M; Pass RH; Silver E; Sampson KJ; Kass RS PLoS One; 2007 Dec; 2(12):e1258. PubMed ID: 18060054 [TBL] [Abstract][Full Text] [Related]
12. Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome. Wang DW; Yazawa K; George AL; Bennett PB Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13200-5. PubMed ID: 8917568 [TBL] [Abstract][Full Text] [Related]
13. A novel mutation L619F in the cardiac Na+ channel SCN5A associated with long-QT syndrome (LQT3): a role for the I-II linker in inactivation gating. Wehrens XH; Rossenbacker T; Jongbloed RJ; Gewillig M; Heidbüchel H; Doevendans PA; Vos MA; Wellens HJ; Kass RS Hum Mutat; 2003 May; 21(5):552. PubMed ID: 12673799 [TBL] [Abstract][Full Text] [Related]
14. Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. Clancy CE; Tateyama M; Kass RS J Clin Invest; 2002 Nov; 110(9):1251-62. PubMed ID: 12417563 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome. Wang DW; Makita N; Kitabatake A; Balser JR; George AL Circ Res; 2000 Oct; 87(8):E37-43. PubMed ID: 11029409 [TBL] [Abstract][Full Text] [Related]
16. beta-Adrenergic action on wild-type and KPQ mutant human cardiac Na+ channels: shift in gating but no change in Ca2+:Na+ selectivity. Chandra R; Chauhan VS; Starmer CF; Grant AO Cardiovasc Res; 1999 May; 42(2):490-502. PubMed ID: 10533584 [TBL] [Abstract][Full Text] [Related]
17. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations. Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774 [TBL] [Abstract][Full Text] [Related]
18. The LQT syndromes--current status of molecular mechanisms. Schulze-Bahr E; Wedekind H; Haverkamp W; Borggrefe M; Assmann G; Breithardt G; Funke H Z Kardiol; 1999 Apr; 88(4):245-54. PubMed ID: 10408028 [TBL] [Abstract][Full Text] [Related]
19. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Kambouris NG; Nuss HB; Johns DC; Tomaselli GF; Marban E; Balser JR Circulation; 1998 Feb; 97(7):640-4. PubMed ID: 9495298 [TBL] [Abstract][Full Text] [Related]
20. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. Huang H; Priori SG; Napolitano C; O'Leary ME; Chahine M Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H288-99. PubMed ID: 21076026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]